SKRIPSI
DIMAS FAJAR AZIZ
STUDI POLA PENGGUNAAN DIAZEPAM
PADA PASIEN GANGGUAN BIPOLAR
(Penelitian dilakukan di Rumah Sakit Jiwa
Dr. Radjiman Wediodiningrat Lawang)
PROGRRAM STUDI FARMASI
FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH MALANG
2019
iv
KATA PENGANTAR
Bismillahirrahmanirrohim
Assalamu’alaikum warohmatullahi wabarokatuh
Puji syukur tercurahkan kepada Allah SWT, Tuhan semesta alam karena
berkat rahmat serta ridloNya, penulis dapat menyelesaikan skripsi yang berjudul
“STUDI POLA PENGGUNAAN DIAZEPAM PADA PASIEN GANGGUAN
BIPOLAR”
Skripsi ini diajukan untuk memenuhi syarat untuk mencapai gelar Sarjana
farmasi pada Program Studi Farmasi Universitas Muhammadiyah Malang. Dalam
penyusunan skripsi ini penulis tidak lepas dari peranan penting pembimbing dan
bantuan dari seluruh pihak. Oleh karena itu, dengan segala kerendahan hati, penulis
ingin mengucapkan terima kasih kepada:
1. Allah SWT, Tuhan semesta alam yang memberikan rahmat, nikmat dan
hidayahNya kepada umatnya, Rosulullah SAW, yang telah menuntun kita
menuju jalan yang lurus.
2. Bapak Faqih Ruhyanudin, M. Kep., Sp.Kep.KMB selaku Dekan Fakultas Ilmu
Kesehatan Universitas Muhammadiyah Malang yang telah memberikan
kesempatan kepada penulis belajar di Fakultas Ilmu Kesehatan Universitas
Muhammadiyah Malang.
3. Ibu Dian Ermawati, M.Farm., Apt selaku ketua program studi Farmasi
Universitas Muhammadiyah Malang beserta jajarannya.
4. Bapak Drs. Didik Hasmono, Apt., MS selaku pembimbing I yang selalu
meluangkan waktu untuk membimbing, mengarahkan, memberikan motivasi
serta menjadi inspirasi untuk menyelesaikan tugas akhir ini dengan baik,
semoga Allah senantiasa memberikan rahmat dan kesehatan.
5. Ibu Hidajah Rachmawati, S.Si., Apt., Sp. FRS selaku Pembimbing II yang
selalu tegas, disiplin dan sabar membimbing serta mengarahkan hingga tugas
akhir ini dapat terselesaikan dengan baik dan tepat waktu, semoga Allah
senantiasa memberikan rahmat dan kesehatan.
v
6. Ibu Dr. Lilik Yusetyani, Dra., Apt., Sp. FRS dan Ibu Firasti Agung N.S.,
M.,Biotech., Apt. selaku penguji I dan II yang memberikan masukkan maupun
saran dalam perbaikan naskah tugas akhir ini agar menjadi lebih baik lagi,
semoga Allah senantiasa memberikan rahmat dan kesehatan.
7. Kedua orang tuaku tercinta, Bapak H. Nur Azizi dan Ibu Hj. Fatimatuz Zahro’.,
SE., yang selalu memberikan motivasi, doa, didikannya selama ini,
pengorbanan, serta kerja kerasnya demi keberhasilan dan kesuksesan putranya.
8. Direktur dan seluruh staf rumah sakit jiwa Dr. Radjiman Wediodiningrat
Lawang yang sangat baik dan banyak membantu kelancaran penelitian skripsi
ini.
9. Tim bipolar dan seluruh teman pejuang klinis, khususnya Dini, Rizki, Amel,
Andri, Juniarti, Aida, Shavira, Eliza dan Citra yang menjadi teman alarm untuk
menyelesaikan tugas akhir dengan cepat dan tepat.
10. Sahabat seperjuangan Aisyah, Dian, Syahrul, Dini, Sultan, Dwi N, Ersita dan
Mutia atas kerja sama dan motivasinya. Sahabat-sahabatku Karir, Adam,
Rizki, Rayhan, Lefi, Dika dan Bagas sudah menjadi sahabat yang baik selama
4 tahun ini.
11. Seluruh teman-teman Sianida 2015, khususnya Farmasi Bohay yang menjadi
teman sejawat dalam perjuangan meraih Sarjana Farmasi. Terimakasih atas 4
tahun yang kita lewati bersama didalam menuntut ilmu dalam suka dan cita.
12. Untuk semua pihak yang belum disebutkan namanya, penulis mohon maaf dan
terima kasih yang sebesar-besarnya. Semua keberhasilan dalam penyelesaian
skripsi ini tidak luput dari bantuan, doa dari kalian semua.
Akhir kata, semoga skripsi ini memberikan manfaat untuk pengetahuan bagi
farmasi klinis maupun pembaca. Penulis menyadari skripsi ini jauh dari sempurna.
Oleh karena itu, kritik dan saran yang membangun sangat penulis harapkan.
Wassalamu’alaikum Wr. Wb.
Malang, 10 Juni 2019
(Dimas Fajar Aziz)
x
DAFTAR ISI
LEMBAR PENGESAHAN .................................................................................. ii
LEMBAR PENGUJIAN ...................................................................................... iii
KATA PENGANTAR .......................................................................................... iv
RINGKASAN……………………………………………………………………vi
ABSTRAK……………………………………………………………………...viii
ABSTRACT .......................................................................................................... ix
DAFTAR ISI ………………………………………………………………….….x
DAFTAR TABEL............................................................................................... xiv
DAFTAR GAMBAR ........................................................................................... xv
DAFTAR LAMPIRAN ...................................................................................... xvi
DAFTAR SINGKATAN ................................................................................... xvii
BAB I PENDAHULUAN ...................................................................................... 1
1.1. Latar belakang .................................................................................................. 1
1.2 Rumusan Masalah ............................................................................................ 4
1.3 Tujuan penelitian ............................................................................................. 4
1.4 Manfaat Penelitian ........................................................................................... 4
BAB II TINJAUAN PUSTAKA ........................................................................... 5
2.1 Definisi Bipolar ................................................................................................ 5
2.2 Klasifikasi Gangguan Bipolar .......................................................................... 6
2.3 Epidemiologi Gangguan Bipolar ..................................................................... 6
2.4 Etiologi Bipolar ................................................................................................ 7
2.4.1 Faktor Biologis ....................................................................................... 7
2.4.1.1 Faktor genetik .................................................................................. 7
2.4.1.2 Faktor Biokimia ............................................................................... 8
2.4.1.2.1 Serotonin .................................................................................. 8
2.4.1.2.2 Dopamin .................................................................................. 9
2.4.1.2.3 Norepinefrin........................................................................... 10
2.4.1.2.4 Gangguan Neurotransmiter lainnya ....................................... 11
2.4.2 Faktor Psikososial ................................................................................. 12
2.4.2.1 Faktor Stres Lingkungan ............................................................... 12
2.4.2.2 Faktor Personal .............................................................................. 13
2.4.2.3 Faktor Psikodinamik pada Depresi dan Mania ............................. 13
2.4.3 Faktor Lainnya dari Depresi ................................................................. 14
xi
2.4.3.1 Faktor Kognitif .............................................................................. 14
2.4.3.2 Faktor Hopelessness ...................................................................... 14
2.5 Anatomi dan Fisiologi Gangguan Bipolar ..................................................... 14
2.6 Patofisiologi Gangguan Bipolar ..................................................................... 17
2.7 Manifestasi Klinis ........................................................................................... 19
2.7.1 Major Depresive Disorder .................................................................... 20
2.7.2 Manic Episode ...................................................................................... 20
2.7.3 Hypomanic Episode .............................................................................. 20
2.8 Diagnosis Bipolar ............................................................................................ 21
2.8.1 Gangguan Bipolar 1 .............................................................................. 21
2.8.2 Bipolar II Disorder ................................................................................ 25
2.8.3 Cyclothymic Disorder ........................................................................... 28
2.9 Penatalaksanaan Gangguan Bipolar ................................................................ 29
2.9.1 Terapi Non Farmakologi ....................................................................... 29
2.9.1.1 Psikoterapi ..................................................................................... 29
2.9.1.2 Electroconvulsive Therapy ............................................................ 29
2.9.2 Terapi Farmakologi ............................................................................... 30
2.9.2.1 Fase Akut ....................................................................................... 31
2.9.2.1.1 Mania dan Episode Campuran ............................................... 31
2.9.2.1.2 Episode Depresi ..................................................................... 31
2.9.2.1.3 Siklus Cepat ........................................................................... 32
2.9.2.2 Terapi pemeliharaan ................................................................. 32
2.9.3 Obat Gangguan Bipolar ........................................................................ 33
2.9.3.1 Mood Stabilizer ............................................................................. 33
2.9.3.1.1 Litium .................................................................................... 33
2.9.3.1.2 Valproat ................................................................................. 34
2.9.3.1.3 Karbamazepin ........................................................................ 34
2.9.3.1.4 Lamotrigin ............................................................................. 35
2.9.3.2 Antidepresan .................................................................................. 35
2.9.3.2.1 Indikasi .................................................................................. 36
2.9.3.2.2 Klasifikasi .............................................................................. 36
2.9.3.2.3 Golongan Obat Antidepresan ................................................ 38
2.9.3.2.3.1 Selective Serotonin Re-uptake Inhibitor ........................ 38
2.9.3.2.3.2 Fluoxetine ...................................................................... 38
2.9.3.2.3.3 Sertraline ........................................................................ 39
2.9.3.2.3.4 Siklik Antidepresan ........................................................ 39
xii
2.9.3.2.3.5 Antagonis Serotonin ...................................................... 39
2.9.3.3 Golongan Obat Antipsikotik ......................................................... 40
2.9.3.3.1 Klozapin................................................................................. 41
2.9.3.3.2 Klobazam ............................................................................... 41
2.9.3.3.3 Quetiapin ............................................................................... 41
2.9.3.3.4 Klorpromazin ......................................................................... 42
2.9.3.3.5 Olanzapin ............................................................................... 43
2.9.3.3.6 Risperidon .............................................................................. 43
2.9.3.4 Ansiolitik ....................................................................................... 44
2.9.3.4.1 Lorazepam ............................................................................. 44
2.9.3.4.2 Alprazolam ............................................................................ 44
2.9.3.4.3 Diazepam ............................................................................... 45
2.9.3.4.3.1 Indikasi ........................................................................... 46
2.9.3.4.3.2 Mekanisme Aksi ............................................................ 47
2.9.3.4.3.3 Farmakokinetik .............................................................. 47
2.9.3.4.3.4 Farmakodinamik ............................................................ 47
2.9.3.4.3.5 Dosis Terapeutik ............................................................ 48
2.9.3.4.3.6 Efek samping ................................................................. 48
2.9.3.4.3.7 Interaksi Obat ................................................................. 49
2.9.3.4.3.8 Sediaan Diazepam .......................................................... 49
2.9.3.4.3.9 Penelitian Diazepam ...................................................... 49
BAB III KERANGKA KONSEPTUAL ............................................................ 51
BAB IV METODE PENELITIAN .................................................................... 53
4.1 Rancangan Penelitian ..................................................................................... 53
4.2 Populasi dan Sampel ...................................................................................... 53
4.2.1 Populasi ................................................................................................ 53
4.2.2 Sampel .................................................................................................. 53
4.2.3 Kriteria Inklusi ...................................................................................... 53
4.2.4 Kriteria Eksklusi ................................................................................... 53
4.3 Bahan Penelitian ............................................................................................ 54
4.4 Instrumen penelitian ....................................................................................... 54
4.5 Tempat dan Waktu Penelitian ........................................................................ 54
4.6 Metode pengumpulan data ............................................................................. 54
4.7 Analisis Data .................................................................................................. 54
4.8 Definisi Operasional ...................................................................................... 55
BAB V HASIL PENELITIAN ........................................................................... 57
xiii
5.1 Data Demografi Pasien Gangguan Bipolar ..................................................... 57
5.1.1 Distribusi Berdasarkan Jenis Kelamin .................................................. 57
5.1.2 Distribusi Berdasarkan Usia Pasien ...................................................... 58
5.1.3 Distribusi Berdasarkan Status Pasien ................................................... 59
5.2 Diagnosa Pasien Gangguan Bipolar ................................................................ 59
5.3 Lama Pasien Gangguan Bipolar Masuk Rumah Sakit .................................... 60
5.4 Keluhan Utama Pasien Gangguan Bipolar ...................................................... 61
5.5 Pola Penggunaan Terapi Diazepam Pasien Rawat Jalan................................. 62
5.5.1 Pola Penggunaan Terapi Kombinasi Dizepam ..................................... 62
5.5.2 Pola Pergantian (Switching) Terapi Diazepam per-oral ....................... 64
5.5.3 Lama Pemeberian Terapi Diazepam per-oral ....................................... 64
5.6 Pola Penggunaan Terapi Diazepam Pasien Rawat Inap .................................. 65
5.6.1 Pola Penggunaan Terapi Tiga Kombinasi Diazepam ........................... 65
5.6.2 Pola Penggunaan Terapi Empat Kombinasi Diazepam ........................ 66
5.6.3 Pola Penggunaan Terapi Lima Kombinasi Diazepam .......................... 68
5.6.4 Pola Penggunaan Terapi Enam Kombinasi Diazepam ......................... 69
5.6.5 Pola Pergantian (Switching) Terapi Diazepam intramuscular .............. 70
5.6.6 Lama Pemberian Terapi Diazepam intramuscular ............................... 74
5.7 Perbandingan Siklus Tidur Pasien Gangguan Bipolar ketika Masuk Rumah
Sakit dengan Kondisi Klinis Sekarang .......................................................... 74
5.8 Kondisi Klinis Sekarang dari Pasien Gangguan Bipolar yang Diterapi dengan
Diazepam ....................................................................................................... 76
BAB VI PEMBAHASAN .................................................................................... 77
BAB VII KESIMPULAN ................................................................................... 93
7.1 Kesimpulan ..................................................................................................... 93
7.2 Saran ................................................................................................................ 93
DAFTAR PUSTAKA .......................................................................................... 94
xiv
DAFTAR TABEL
Halaman
Table II.1 Tingkat prevalensi seumur hidup gangguan depresi ............................. 7
Table II.2 Struktur Otak yang Terlibat dalam Respon Emosi ............................. 15
Table II.3 Klasifikasi obat antidepresan .............................................................. 28
Table II.4 Sediaan Diazepam ............................................................................... 40
Table V.1 Distribusi jenis kelamin ...................................................................... 58
Table V.2 Distribusi Usia .................................................................................... 58
Table V.3 Distribusi Status .................................................................................. 59
Table V.4 Diagnosa .............................................................................................. 59
Table V.5 Lama Pasien Masuk Rumah Sakit ....................................................... 61
Table V.6 Keluhan Utama Pasien ........................................................................ 61
Table V.7 Pola Penggunaan Terapi Pasien Rawat Jalan ...................................... 62
Table V.8 Pola Penggunaan Terapi Kombinasi Pasien Rawat Jalan ................... 63
Table V.9 Pola Switch Terapi Diazepam Pasien Rawat Jalan ............................. 64
Table V.10 Lama Pemberian Terapi Diazepam Pasien Rawat Jalan ................... 64
Table V.11 Pola Penggunaan Terapi Pasien Rawat Inap ..................................... 65
Table V.12 Pola Penggunaan Terapi Kombinasi 3 Obat Pasien Rawat Inap ....... 66
Table V.13 Pola Penggunaan Terapi Kombinasi 4 Obat Pasien Rawat Inap ....... 66
Table V.14 Pola Penggunaan Terapi Kombinasi 5 Obat Pasien Rawat Inap ....... 68
Table V.15 Pola Penggunaan Terapi Kombinasi 6 Obat Pasien Rawat Inap ....... 69
Table V.16 Pola Switch Terapi Diazepam Pasien Rawat Inap ............................ 70
Table V.17 Lama PemberianTerapi Diazepam Pasien Rawat Inap ..................... 74
Table V.18 Efek Pemberian Siklus Tidur Pasien ................................................. 74
Table V.19 Kondisi Klinis Sekarang Pasien Gangguan Bipolar .......................... 76
xv
DAFTAR GAMBAR
Halaman
Gambar 2.1 Siklus suasana hati pasien bipolar ..................................................... 5
Gambar 2.2 Model transmisi genetik penularan gangguan bipolar ....................... 8
Gambar 2.3 Proyeksi dopaminergik utama dalam CNS ...................................... 10
Gambar 2.4 Mekanisme Patofisiologi GABA ..................................................... 12
Gambar 2.5 Ilustrasi daerah otak utama .............................................................. 14
Gambar 2.6 Amygdala & Hipocampus .............................................................. 15
Gambar 2.7 Dorsolateral Prefrontal Cortex ......................................................... 16
Gambar 2.8 Anterior Cingulate & Subgenual Anterior Cingulate ...................... 16
Gambar 2.9 Jalur serotonin dan dopamin dalam otak ......................................... 17
Gambar 2.10 Perubahan fungsional otak pada orang dengan bipolar ................. 18
Gambar 2.11 Kondisi Normal & Kondisi Inflamasi Peripheral Saraf Glial ........ 18
Gambar 2.12 Struktur kimia Asam Valproat ....................................................... 34
Gambar 2.13 Struktur kimia Karbamazepin ........................................................ 35
Gambar 2.14 Struktur kimia Lamotrigin ............................................................. 35
Gambar 2.15 Struktur kimia Fluoxetin ................................................................ 30
Gambar 2.16 Struktur kimia Traxodon................................................................ 31
Gambar 2.17 Struktur kimia Nefaxodon ............................................................. 31
Gambar 2.18 Struktur kimia Klozapin ................................................................ 32
Gambar 2.19 Struktur kimia Quetiapin ............................................................... 33
Gambar 2.20 Struktur kimia Klorpromazin ......................................................... 34
Gambar 2.21 Struktur kimia Olanzapin ............................................................... 34
Gambar 2.22 Struktur kimia Lorazepam ............................................................. 35
Gambar 2.23 Struktur kimia Alprazolam ............................................................ 36
Gambar 2.24 Struktur kimia Diazepam ............................................................... 45
Gambar 3.1 Skema kerangka konseptual ............................................................ 41
Gambar 3.2 Skema kerangka operasional ........................................................... 42
Gambar 5.1 Skema inklusi dan eksklusi……...…………………………………57
xvi
DAFTAR LAMPIRAN
LAMPIRAN 1 : Daftar Riwayat Hidup ............................................................ 99
LAMPIRAN 2 : Surat Pernyataan .................................................................. 100
LAMPIRAN 3 ; Surat Keterangan Selesai Penelitian ................................... 101
LAMPIRAN 4 : Surat Laik Etik...................................................................... 102
LAMPIRAN 5 : Lembar Pengumpul Data ..................................................... 103
xvii
DAFTAR SINGKATAN
APA : American Psychiatric Association
BDNF : Brain Derived Neurotrophic Factor
BDZ : Benzodiazepin
BPJS : Badan Penyelenggara Jaminan Sosial
CBT : Cognitif Based Therapy
CNS : Central Nervous System
CSF : Cerebrospinal Fluid
DSM : Diagnostic and Stastical Manual of Bipolar Disorder
D2 : Dopamin 2
D-M-I : Depression Mania Well Interval
DZ : Diazepam
ECT : Electro Convulsive Therapy
EEG : Elektroensefalogram
FDA : Food Drug Association
GABA : Gamma Amino Butyrac Acid
GAD : Glutamat dekarboksilase
GCS : Glasgow Coma Scale
GDNF : Glial Cell Line-Derived Neurotrophic Factor
H1 : Histamin1
KRS : Keluar Rumah Sakit
LPD : Lembar Pengumpul Data
MAO : Mono Amin Oksidase
MRI : Magnetic Resonance Imaging
MRS : Masuk Rumah Sakit
xviii
NIMH : National Institute of Mental Health
OCD : Obsessive Compulsive Disorder
PET : Positron Emission Tomographic
PTSD : Post traumatic stress disorder
REM : Rapid Eye Movement
RISKESDAS : Riset Kesehatan Dasar
RMK : Rekam Medik Kesehatan
RR : Respiratory Rate
TD : Tekanan Darah
SSP : Sistem Saraf Pusat
94
DAFTAR PUSTAKA
Ahuja, Niraj. 2011. A Short Text Book Psychiatry Seventh Edition. India: Jaypee
Brothers Medical Publishers (P) Ltd.
Alfredo H. Cía, Juan Carlos Stagnaro, Sergio Aguilar Gaxiola, Horacio Vommaro,
Gustavo Loera, María Elena Medina-Mora, Sebastían Sustas, Corina Benjet,
Ronald C. Kessler,. 2017. Lifetime prevalence and age-of-onset of mental
disorders in adults from the Argentinean Study of Mental Health
Epidemiology. Springer. Jerman
APA. (2000). Diagnostic nd Statistical Manual of MENTAL DISORDERS
Fourth Edition Text Revision. Washington DC: American Psychiatric
Association.
APA (American Psychiatric Association), 2010. Practice Guideline For The
Treatment of Patients with Bipolar Disorder Second Edition. American
Psychiatric Publishing.
APA (American Psychiatric Association), 2013. Diagnostic and Statistical
Manual of Mental Disorders Fifth Edition. United States: American
Psychiatric Publishing.
APA. (2017). What Are Bipolar Disorders? Retrieved from American
Psychiatryc Association: http://www.psychiatry.org/patients-
families/bipolar-disorder/what-are-bipolar-disorders
Aubry, Jean et al., 2007. Pharmacotherapy of Bipolar Disorders. Chichester, UK
: John Wiley & Sons, Ltd. DOI: 10.1002/9780470510421.
Ayano, G. 2016. Bipolar Disorders and Carbamazepine: Pharmacokinetics,
Pharmacodynamics, Therapeutic Effects and Indications of Carbamazepine:
Review of Articles. Journal of Neuropsychopharmacology & Mental
Health. DOI: 10.4172/2472-095X.1000112
Ayano, G. 2016. Common Neurotransmiters: Criteria for Neurotransmiters, Key
Locations, Classifications and Functions. Advances in Psychology and
Neuroscience. doi: 10.11648/j.apn.20160101.11 Volume 1, Nomor 1,pp. 1-
5.
Ayano, G. 2016. Dopamine: Receptors, Functions, Synthesis, Pathways, Locations
and Mental Disorders: Review of Literatures. J Ment Disord Treat 2. ISBN
: 2471-271X. Volume 2
Badria, F., 2012. Pharmacotherapy. Croatia: In Tech.
Baxter, K., 2008. Stockley’s Drug Interactions Eighth Edition. USA:
Pharmaceutical press.
95
Beniclo, R., Rodriguez, M., Vieira, R., & Kapzincski, J. (2004).
Neuropathological and neurochemical. Rev Bras Pisquiatr, 8-108.
Bowden, C. (2003). Acute and maintenance treatment with mood stabiliziers.
International Journal of Neuropsychopharmacology, 269-275.
Boyd, R., and Dunn, K., 2015. Understanding Bipolar Disorder. London: MIND.
Buoli, M., et al., 2017. Have antipsychotics a different speed of action in the
acute treatment of mania? A single-blind comparative study. SAGE.
DOI: 10.1177/0269881117705098
Brunton, L., Parker, K., Blumenthal, D., Buxton, I., 2010. Goodman & Gilman:
Manual Farmakologi dan Terapi (Sukandar, E.Y. Trans). Jakarta: EGC.
Coryel, et al., 2009. Anxiety and Outcome in Bipolar Disorder. American Journal
of Psychiatry. DOI: 10.1176/appi.ajp.2009.09020218
CRUK (Cancer Research United Kingdom), 2014. Diagram Showing The Lobes
of The Brain. Wikimedia commons. https://commons.wikimedia.org/wiki
/File:Diagram_showing_the_lobes_of_the_brain_CRUK_308.svg, diakses
tanggal 10 September 2019.
Colombo, C. et al., 1999. Rate of switch from depression into mania after
therapeutic sleep deprivation in bipolar depression. Psychiatry Research.
DOI: 10.1016/S0165-1781(99)00036-0
Colom, F dan Lam, D, 2005. Psychoeducation: Improving Outcomes in Bipolar
Disorder. Eur Psychianty. 20 (5-6). Farmaka volume 15 nomor 3
Darlene D. Pedersen, MSN, APRN, PMHCNS. 2014. Psych Notes ( Clinical
Pocket Guide). China. F. A. Davis Company.
DeBattista C, MD, 2009. Basic & Clinical Pharmacology, Eleventh Edition.
USA. Mc. Graw hill.
Depkes RI (Departemen Kesehatan Republik Indonesia), 2007. Pharmaceutical
Care Untuk Penderita Gangguan Depresif. Bakti Husada: 616.891.8 Ind p
Drayton, S.J., and Weinstein, B., 2008. Pharmacotherapy A Pathophysiologic
Approach Seventh Edition. USA: The Mc Graw-Hill Companies.
Ekholm, J., 2005. Molecular Genetics of Bipolar Disorder and Related Traits.
Finland: National Public Health Institute.
Fiorillo, A., et al 2013. Efficacy of supportive family interventions in bipolar
disorder: a review of the literature. Department of Psychiatry, University
of Naples SUN, Naples, Italy
Flavio Guzman, MD. 2017. Long-Acting Injectable Antipsychotics: A Summary
for Prescribers. Psychopharmacology institute
96
Grof, Paul. 2010. Investigating Children at High Risk for Bipolar and Psychotic
Disorders: Findings and Implications. The Canadian Journal of Psychiatry.
DOI: 10.1177/070674371005500801
Grunze. H, et al. 2009. The World Federation of Societies of Biological
Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar
Disorders: Update 2009 on the Treatment of Acute Mania. Informa
Healthcare, Taylor & Francis AS. UK. ISSN 1562-2975 print/ISSN 1814-
1412
Hilty, D., M., et al., 2006. A Review of Bipolar Disorder in Adults. University of
california: Psychiatry. [email protected]
Ikawati, Z., 2011. Farmakoterapi Penyakit Sistem Saraf Pusat. Yogyakarta:
Bursa Ilmu.
Jiwo, T., 2012. Gangguan jiwa bipolar: Panduan bagi pasien, keluarga dan
teman dekat. Purworejo: Pusat Pemulihan dan Pelatihan Bagi Penderita
Gangguan Jiwa
Katona, C., et al., 2008. Phychiatry At a Glance Fourth Edition (Noviyanti, Cut
& Hartiansyah, V, Trans). Jakarta: Erlangga.
Katzung, et al 2012. Basic & Clinical Pharmacology Twelfth Edition. United
States: The McGraw-Hill Companies, Inc.
Kalat, James W. (2001). Biological Psychology. Bipolar disorder, 434-436
Kay, J & Tasman, A., 2006. Essentials Of Psychiatry. England: John Wiley &
Sons.
Ketter, Tarrence A. 2010. Handbook of diagnosis and treatment of bipolar
disorders. Washington DC : American Psychiatry Pub
Kring, A.M., Johnson, S.L., Davisonm, G.C., and Neale, J..M., 2012. Abnormal
Psychology Twelfth Edition. United States: John Wiley & Sons, Inc.
Lacro. J. P., Farhadian. S., Alldredge. B. K., Corelli. R.L., Ernest. B. J., Kradjan.
W. A., et al., 2013. Applied Therapeutics The Clinical Use of Drugs Tenth
Edition. USA: Lippincott Williams & Wilkins, a Wolters Kluwer
Luellmann, H., Hein, L., Mohr, K., 2005. Color Atlas of Pharmacology 3rd
edition, revised and expanded (Bieger, D., trans). New York: Thieme
Stuttgart.
Maletic, V dan Raison C. 2014. Integrated Neurobiology Of Bipolar Disorder.
USA: Frontiers in psychiatry. Doi: 10.3389/fpsyt.2014.00098 Volume 5 :
98
Marcovitz, Hal. 2009. Bipolar Disorder. San Diego, CA : Reference Point Press
97
Mintz, David. 2015. Bipolar Disorder: Overview, Diagnostic Evaluation and
Treatment. MD and the Austen Riggs Center
McMurry, J., 2016. Organic Chemistry Ninth Edition. USA: Cengage Learning.
Meltzer. H., 2009. Basic & Clinical Pharmacology Eleventh Edition. US: The
Mc Graw-Hill Companies
NIMH (National Institute of Mental Health), 2012. Bipolar Disorder in Adults.
United States: Department of Health and Human Service National Institute of
Health.
Neal, M.J., 2005. Medical Pharmacology At a Glance (Surapsari, J. Trans).
Jakarta: Erlangga.
PE, Kate. 2017. Foods Responsible for Improving our Mood.
Priyatni, W.N. 2016. Berapa Kebutuhan Diazepam untuk memenuhi Pelayanan
Kesehatan di Indonesia. JURNAL MANAJEMEN DAN PELAYANAN
FARMASI (Journal of Management and Pharmacy Practice). DOI:
10.22146/jmpf.359
Riskesdas (Riset Kesehatan Dasar), 2013. Badan Penelitian dan Pengembangan
Kesehatan. Jakarta: Departemen Kesehatan RI
Sadock, B.J., and Sadock, V.A., 2010. Kaplan & Sadock Buku Ajar Psikiatri
Klinis Edisi Kedua. Jakarta: EGC.
Sadock, B. J., and Sadock, V. A., 2015. Kaplan And Sadock’s Synopsis Of
Psychiatry Eleventh Edition. Wolters Kluwer.
Shannon, J.D. and Benjamin, L.W., 2008. Pharmacotherapy A Pathophysiologic
Approach Seventh Edition. USA: The Mc Graw-Hill Companies.
Stephen M. Stahl., 2017. Stahl’s Essential Psychopharmacology. Prescriber’s
Guide, 6th adition. California. Cambridge University Press.
Strakowski, S. et al., 2012. The functional neuroanatomy of bipolar disorder: a
consensus model: Functional neuroanatomy of bipolar disorder. Bipolar
Disorders. DOI: 10.1111/j.1399-5618.2012.01022.x
Sweetman, S.C., 2009. Martindale The Complete Drug Reference Thirty-Sixth
Edition. London: The Pharmaceutical Press.
Tatro, D.S., 2003. A to Z Drug Facts: Facts and Comparison. St. Louis.
Taylor, E.H., 2006. Atlas of Bipolar Disorder. United Kingdom: Taylor & Francis
Group.
Taylor, K. 2016. Bipolar Disorders: A Balanced Perspective. Bipolar Disorder:
Open Access. DOI: 10.4172/2472-1077.1000e106
98
Thamayanti, Dr K et al., 2017. Sleep Pattern and Sleep Quality Observed With Tab.
Diazepam and Tab. Alprazolam in Patients Treated For Insomnia. IOSR
Journal of Dental and Medical Sciences (IOSR-JDMS). DOI:
0.9790/0853-160408136142
Purba, R.T., 2016. Pocket Synopsis: Obat di Indonesia. Banjarbaru: PT. Grafika
Wangi Kalimantan.
Videbeck, S.L., 2011. Psychiatric–Mental Health Nursing Fifth Edition. China:
Wolters Kluwer Health & Lippincott Williams & Wilkins.
Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., and DiPiro, C.V., 2015.
Pharmacotherapy Handbook Ninth Edition. United States: McGraw-Hill
Education.
Wingard, Louise et al., 2018. Initiation and long-term use of benzodiazepines
and Z-drugs in bipolar disorder. Bipolar Disorders. DOI:
10.1111/bdi.12626
WHO (World Health Organization). 2009. Pharmacological treatment of mental
disorders in primary health care. Geneva : WHO
WHO (World Health Organization). 2017. Mental Disorder.
http://www.who.int/mediacentre/factsheets/fs396/en/. Diakses tanggal 9
September 2019